News of a significant earnings beat propelled Regeneron Pharmaceuticals (NASDAQ: REGN) to a nearly 5% share price gain on the second trading day of the week. The company posted its fourth-quarter and ...

Shares of Regeneron Pharmaceuticals have plunged more than 30% over the past six months, but one Wall Street analyst believes the sell-off has created an attractive buying opportunity. While ...

(NASDAQ:REGN) stands against other best stocks to buy ... of the 10 best stocks to buy and hold for 2025, we used the Finviz stock screener to look for stocks that analysts believe will gain ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Stock analysts at Leerink Partnrs upped their Q1 2025 earnings per share (EPS) estimates for Regeneron Pharmaceuticals in a ...

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection ...

s (NASDAQ:REGN) proven track record of success in new drug discovery and development, Baron Health Care Fund is optimistic that the pipeline will yield success that could drive the stock up.

While Regeneron has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question ...

Secondly, to support the stock price, Regeneron management announced the authorization of an additional $3 billion, which will go towards a share buyback program. The New York-based company ...

Investors in Regeneron Pharmaceuticals, Inc. (Symbol: REGN) saw new options begin trading today, for the March 14th expiration. At Stock Options Channel, our YieldBoost formula has looked up and ...